Apixaban safety and adherence for atrial fibrillation patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests how well patients with atrial fibrillation take their apixaban medication and whether it is safe. It aims to see if using apixaban for the first time works well without causing bleeding problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have atrial fibrillation not caused by a heart valve problem.
- You are starting apixaban for the first time.
- You are medically stable (no recent serious bleeding or blood disorders).
- You do not have a cancer, liver disease, or are on dialysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This study tests whether a smartphone app that teaches patients about their blood thinner (apixaban, also called Eliquis) helps them take it more regularly. If you have atrial fibrillation and take apixaban, this app might help you manage your medication better.
This trial tests whether apixaban, a blood thinner, works well for people with atrial fibrillation who also have heart or circulation conditions. It uses a smartphone app to help track your treatment.
This study looks at how the blood thinner apixaban (Eliquis) works in Asian patients with atrial fibrillation. By understanding how the drug is processed by the body, doctors may be able to personalize dosing for better safety and effectiveness.
This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.
This study tests if apixaban (a newer blood thinner) is safer and works as well as warfarin (a standard blood thinner) for patients on peritoneal dialysis who have atrial fibrillation (an irregular heartbeat). It aims to reduce the risk of stroke and bleeding.
Hear when a new Nonvalvular Atrial Fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.